Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Survey

SimBioSys® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022


SimBioSys, the precision oncology company behind the 4D Tumor Modelingtm technology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium (SABCS). SimBioSys will also exhibit at booth 823.

The studies covering six separate poster presentations at SABCS are based on data from both internal and external validation studies of SimBioSys' proprietary platform. The results include collaborations with top cancer research institutions, multi-institutional analysis, enhanced visualization, and volumetric prediction capabilities to aid surgical planning as well as novel biomarkers.

"Our presentations at SABCS demonstrate our multidisciplinary approach and the clinical utility of our 4D modeling technology. We are incredibly proud of the research and clinical collaborations with key leaders in breast cancer and the impact our technology can have in breast cancer care," said Dr. Anuja Antony, Chief Medical Officer of SimBioSys.

The company will be presenting abstracts validating their visualization and prediction technology which offers pCR prediction and recurrence free survival, surgical planning and biomarker development. Details about the presentations can be found below:

P1-04-07: pCR Score: a novel prognostic method to estimate the predictive probability of pCR in early-stage breast cancer patients

Peterson J, et. al.

When: Tuesday December 6, 2022

Where: Poster session 1 ? Hall 1

Research conducted with: Berry Consultants, LLC; University of Chicago; Northwest Community Healthcare; Baylor Scott & White Health; University of Cincinnati; University of North Carolina, Lineberger Comprehensive Cancer Center; Springfield Clinic; University of Arizona Cancer Center.

P1-04-08: Independent validation of a novel, non-invasive approach to predict pathologic complete response (pCR) in a blinded, prospectively-run single center trial

Kuzmiak C, et. al.

When: Tuesday December 6, 2022

Where: Poster session 1 ? Hall 1

Research conducted with: University of North Carolina, Lineberger Comprehensive Cancer Center

P4-02-19: Development of a novel imaging biomarker to ascertain responsiveness to immunotherapy

Cook D, et. al.

When: Thursday December 8, 2022

Where: Poster session 2 ? Hall 1

P4-02-24: A 3D visualization and prediction device for breast cancer surgeons and their patients

Parker A, et. al.

When: Thursday December 8, 2022

Where: Poster session 2 ? Hall 1

P4-02-29: A 3D visualization method for breast cancer surgeons and patients

Parker A, et. al.

When: Thursday December 8, 2022

Where: Poster session 2 ? Hall 1

P6-01-36: Validation of prognostic platform to further refine identification high risk patients indicated for chemotherapy free treatment in early-stage breast cancer

Peterson J, et. al.

When: Friday December 9, 2022

Where: Poster session 2 ? Hall 1

Research conducted with: NorthShore University Health System.

About SimBioSys:

SimBioSys is a technology company deploying a combination of artificial intelligence and biophysics-based simulations to improve our understanding of cancer. By virtualizing cancer, SimBioSys aims to empower clinicians and patients with a comprehensive understanding of the disease and treatment options.


These press releases may also interest you

at 02:05
Animal wound care Market Overview: The global Animal wound care Market is currently valued at USD 1.85billion and is expected to reach USD 1.00 billion by the end of 2029, growing at a CAGR of 7.1% over the next decade. Animal wound care is one of...

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to...

at 01:30
Consolidated sales revenue of ?4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales Sales revenue for brand-name medicines reached ?3.694 billion, up 12.5% (+8.9% at CERi), and ?1.182 billion for generics, up 2.0%...

at 01:15
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the formation of a scientific advisory board consisting of four world-renowned...

at 01:05
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2022 (period ended December 31, 2022). Takeda chief financial officer, Costa Saroukos, commented: "Our third-quarter performance demonstrates...

at 01:00
SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused...



News published on 6 december 2022 at 06:05 and distributed by: